Skip to Main Content

Author Details

Nathan Bahary
University of Pittsburgh
1989
138
45
PMIDPaper TitleJournal TitlePublished Year
37939140Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer.Clin Cancer Res2024
36316507ASO Visual Abstract: Neoadjuvant Therapy Versus Upfront Resection for Non-pancreatic Periampullary Adenocarcinoma.Ann Surg Oncol2023
37535272Defining the Values and Quality of Life of Cancer Survivors Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: An International Survey Study.Ann Surg Oncol2023
37534996Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration.Clin Cancer Res2023
37192435Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium.J Clin Oncol2023
37379764Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial.ESMO Open2023
36610939The use of angiotensin system inhibitors correlates with longer survival in resected pancreatic adenocarcinoma patients.HPB (Oxford)2023
36804826No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer.HPB (Oxford)2023
36416848Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy.JAMA Surg2023
35925536Neoadjuvant Therapy Versus Upfront Resection for Nonpancreatic Periampullary Adenocarcinoma.Ann Surg Oncol2023
33278573Tumor Size Differences Between Preoperative Endoscopic Ultrasound and Postoperative Pathology for Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma Predict Patient Outcome.Clin Gastroenterol Hepatol2022
35737385Adaptive Dynamic Therapy and Survivorship for Operable Pancreatic Cancer.JAMA Netw Open2022
34991708Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis.Clin Epigenetics2022
34291365The Role of Adjuvant Chemotherapy Following Right Hemicolectomy for Non-metastatic Mucinous and Nonmucinous Appendiceal Adenocarcinoma.J Gastrointest Surg2022
32661298Intratumoral budding and automated CD8-positive T-cell density in pretreatment biopsies can predict response to neoadjuvant therapy in rectal adenocarcinoma.Mod Pathol2021
33770459Current Management of Appendiceal Neoplasms.Am Soc Clin Oncol Educ Book2021
33893740Predictors of early recurrence following neoadjuvant chemotherapy and surgical resection for localized pancreatic adenocarcinoma.J Surg Oncol2021
33748894Optimal Management of Resectable Pancreatic Head Cancer in the Elderly Patient: Does Neoadjuvant Therapy Offer a Survival Benefit?Ann Surg Oncol2021
33523364A Pancreatic Cancer Multidisciplinary Clinic Eliminates Socioeconomic Disparities in Treatment and Improves Survival.Ann Surg Oncol2021
34559451Encouraging long-term survival following autophagy inhibition using neoadjuvant hydroxychloroquine and gemcitabine for high-risk patients with resectable pancreatic carcinoma.Cancer Med2021
34002944SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma.Clin Transl Sci2021
34336666Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan.Front Oncol2021
34231222Optimal management of patients with operable pancreatic head cancer: A Markov decision analysis.J Surg Oncol2021
34027585Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer.Ann Surg Oncol2021
33103242Neoadjuvant therapy versus upfront surgery for early-stage left-sided pancreatic adenocarcinoma: A propensity-matched analysis from a national cohort of distal pancreatectomies.J Surg Oncol2021
33386547Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma Lessens the Deleterious Effect of Omission of Adjuvant Chemotherapy.Ann Surg Oncol2021
33231769Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation in Localized Pancreatic Cancer: A Case-Control Matched Analysis.Ann Surg Oncol2021
30971436Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures.Gut2020
31840257Impact of adjuvant chemotherapy regimen on survival outcomes in immunohistochemical subtypes of ampullary carcinoma.J Surg Oncol2020
31799875Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.AJR Am J Roentgenol2020
31765263Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study.J Clin Oncol2020
31792715Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer.Ann Surg Oncol2020
33305081Patterns of Failure After Adjuvant Stereotactic Body Radiation Therapy for Pancreatic Cancer With Close or Positive Margins.Adv Radiat Oncol2020
32706635Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma.J Clin Oncol2020
32205483Automated Quantitation of CD8-positive T Cells Predicts Prognosis in Colonic Adenocarcinoma With Mucinous, Signet Ring Cell, or Medullary Differentiation Independent of Mismatch Repair Protein Status.Am J Surg Pathol2020
32376853KRAS amplification in metastatic colon cancer is associated with a history of inflammatory bowel disease and may confer resistance to anti-EGFR therapy.Mod Pathol2020
32318949CA19-9 Change During Neoadjuvant Therapy May Guide the Need for Additional Adjuvant Therapy Following Resected Pancreatic Cancer.Ann Surg Oncol2020
32222859Predictors of Disease Progression or Performance Status Decline in Patients Undergoing Neoadjuvant Therapy for Localized Pancreatic Head Adenocarcinoma.Ann Surg Oncol2020
30561756A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma.Cancer2019
30836094Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.Gastroenterology2019
30691849Review and Update on the Role of Peritoneal Cytology in the Treatment of Gastric Cancer.J Surg Res2019
28772092A Pilot Trial of Early Specialty Palliative Care for Patients with Advanced Pancreatic Cancer: Challenges Encountered and Lessons Learned.J Palliat Med2018
30160983CT Radiogenomic Characterization of the Alternative Lengthening of Telomeres Phenotype in Pancreatic Neuroendocrine Tumors.AJR Am J Roentgenol2018
29967636Overweight or Obese Individuals at Eighteen Years of Age Develop Pancreatic Adenocarcinoma at a Significantly Earlier Age.Gastroenterol Res Pract2018
29986726Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer.J Transl Med2018
30067863Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma.Cancer2018
31011674Initial Results of a Prospective Study of Adjuvant Pancreatic Stereotactic Body Radiation Therapy for Close or Positive Margins.Adv Radiat Oncol2018
29360161Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy.Cancer2018
29520435A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma.Cancer Chemother Pharmacol2018
29486199Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times.Gastroenterology2018
  • 1 - 50 of 138

Recommended Authors

Tuo Zhang
Weill Cornell Medical College.
Career Start Year 2013
Number of shared co-authors 1
Ashton A Connor
Houston Methodist Hospital
Career Start Year 2012
Number of shared co-authors 0
Johannes Haybaeck
Institute of Pathology, Medical University of Innsbruck
Career Start Year 2007
Number of shared co-authors 0
John Paul Shen
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 5
Kurt W Fisher
University of Nebraska Medical Center
Career Start Year 2004
Number of shared co-authors 0
Itzhak Avital
Goldman School of Medicine, Ben Gurion University
Career Start Year 2001
Number of shared co-authors 0
Pingfu Fu
Case Western Reserve University
Career Start Year 2000
Number of shared co-authors 0
Christopher J Howlett
Western University
Career Start Year 1999
Number of shared co-authors 2
Eric A Collisson
University of California san francisco
Career Start Year 1999
Number of shared co-authors 7
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 0
Thomas J George
UF Health Cancer Center
Career Start Year 1998
Number of shared co-authors 9
Feng Zhu
Basic Medical College, Qingdao University
Career Start Year 1998
Number of shared co-authors 0
Hai Hu
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Career Start Year 1996
Number of shared co-authors 2
Sung Tae Kim
Busan Paik Hospital, Inje University
Career Start Year 1996
Number of shared co-authors 4
Udo Rudloff
Center for Cancer Research, National Cancer Institute
Career Start Year 1994
Number of shared co-authors 0
Nabeel Bardeesy
Massachusetts General Hospital
Career Start Year 1992
Number of shared co-authors 2
Weei-Yuarn Huang
Nova Scotia Health Authority
Career Start Year 1992
Number of shared co-authors 0
Kerrington D Smith
Dartmouth-Hitchcock Medical Center
Career Start Year 1991
Number of shared co-authors 0
Oliver F Bathe
Cumming School of Medicine, University of Calgary
Career Start Year 1991
Number of shared co-authors 1
Suzanne Carreira
The Institute of Cancer Research
Career Start Year 1990
Number of shared co-authors 0
Sun Young Kim
Asan Medical Center, University of Ulsan College of Medicine
Career Start Year 1988
Number of shared co-authors 4
Louis Gaboury
Institute for Research in Immunology and Cancer (IRIC), University of Montreal
Career Start Year 1986
Number of shared co-authors 0
Katherine L Nathanson
Perelman School of Medicine, University of Pennsylvania, USA Abramson Cancer Center
Career Start Year 1986
Number of shared co-authors 2
Christopher L Corless
Oregon Health & Science University
Career Start Year 1985
Number of shared co-authors 3
Andrew M Lowy
University of California San Diego
Career Start Year 1985
Number of shared co-authors 6
Steven Gallinger
Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto
Career Start Year 1983
Number of shared co-authors 3
Francisco X Real
Spanish National Cancer Research Centre-CNIO
Career Start Year 1983
Number of shared co-authors 0
David M Berman
Queen's University
Career Start Year 1982
Number of shared co-authors 3
David J Adams
Wellcome Sanger Institute
Career Start Year 1980
Number of shared co-authors 5
William E Grizzle
University of Alabama at Birmingham
Career Start Year 1974
Number of shared co-authors 2

Collaborators

Amit Arora
University of Arizona
Co-authored papers 3
Khanh Nguyen
Department of Pharmaceutical Technology and Biopharmacy, University of Groningen
Co-authored papers 3
Somak Roy
University of Cincinnati College of Medicine
Co-authored papers 3
Siraj M Ali
Foundation Medicine
Co-authored papers 2
Daniel D Von Hoff
Co-authored papers 2
Jeffrey S Ross
Foundation Medicine
Co-authored papers 2
Georgios I Papachristou
The Ohio State University, Wexner Medical Center
Co-authored papers 2
Simion I Chiosea
University of Pittsburgh
Co-authored papers 2
Michael J O'Connell
NSABP Foundation
Co-authored papers 2
Lance A Liotta
Co-authored papers 2
David C Whitcomb
University of Pittsburgh Medical Center
Co-authored papers 2
Raja R Seethala
University of Pittsburgh Medical Center-Presbyterian
Co-authored papers 1
Jordan W Smoller
Center for Genomic Medicine, Massachusetts General Hospital
Co-authored papers 1
Joel S Schuman
NYU Grossman School of Medicine
Co-authored papers 1
H Ishikawa
Mie University School of Medicine, NYU School of Medicine, New York Medical College, New York University School of Medicine, Oregon Health & Science University, Tufts University School of Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh School of Mediine
Co-authored papers 1
William S Talbot
Co-authored papers 1
Toni K Choueiri
Dana-Farber Cancer Institute
Co-authored papers 1
Xiangyun Wei
University of Pittsburgh
Co-authored papers 1
Parminder Singh
Mayo Clinic
Co-authored papers 1
Gadi Wollstein
NYU College of Arts and Sciences
Co-authored papers 1
Alexandra Drakaki
David Geffen School of Medicine at university of california los angeles
Co-authored papers 1
Stephen E Lincoln
Co-authored papers 1
Stephen J P Pratt
University of Maryland School of Medicine
Co-authored papers 1
Steve D M Brown
Mary Lyon Centre Harwell Science and Innovation Campus Oxfordshire UK.
Co-authored papers 1
Mark W Kieran
Boston Children's Hospital and Harvard Medical School
Co-authored papers 1
Donghun Shin
Co-authored papers 1
Puwat Charukamnoetkanok
Mettapracharak (Wat Rai Khing) Hospital
Co-authored papers 1
Changqing Ma
Co-authored papers 1
Stuart H Orkin
Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School
Co-authored papers 1
Daniel J Weisenberger
Co-authored papers 1
Release 1.2